Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
2024 · Nature Medicine · 69 citations
https://doi.org/10.1038/s41591-024-03086-4
M
Marice Alcantara
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
30
Papers
790
Citations
12
h-index
12
i10-index
Marice Alcantara is an academic researcher from City Of Hope National Medical Center. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Peptidase Inhibition and Analysis & Renal cell carcinoma treatment. The author has an h-index of 12, co-authored 26 publications.
ORCID: 0000-0003-1853-2884Papers by this author
worksTargeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy
2024 · Frontiers in Immunology · 16 citations
https://doi.org/10.3389/fimmu.2023.1274781
Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy
2020 · Molecular Therapy · 12 citations
https://doi.org/10.1016/j.ymthe.2020.11.026
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat